CTC BIO and Chifu Ink Deal to Launch One-two Tab in Taiwan

The Taiwanese pharmaceutical distributor Chifu and the Korean pharmaceutical company CTC BIO have inked an exclusive supply deal for CTC BIO's medication for premature ejaculation, One-two Tab.

Chifu was founded in 1961 and has a long history of providing neurological medications. More recently, the company has expanded to offer neuropathic therapies and pain management. A solid basis for this new endeavour was laid by the two businesses' prior collaboration on an oral dissolving film (ODF) containing cannabidiol (CBD) in 2021.

CTC BIO has been focussing on the drug's worldwide rollout since its July 30 debut in Korea.The organisation intends to get authorisation from the Taiwan Food and Drug Administration (TFDA) prior to initiating comprehensive distribution throughout the area.Over the following five years, CTC BIO anticipates that the arrangement would bring in at least $30 million (40.9 billion won) in income to Taiwan.

"With this agreement with Chifu, we are officially launching One-two Tab's global expansion," a business representative stated. "Our goal is to strategically enter Asia through the Taiwanese market, and then expand to North America, Europe, and other regions."

"Our partnership with Chifu is a testament to the excellence, market potential, and convenience of our One-two Tab," added CTC BIO CEO Kim Young-deok.According to Kim, the business would keep working to swiftly grow its market share in Taiwan's urology industry.